New mRNA platform maintains drug efficacy in aging and obese patients

Mar 10, 2026

Scientists developed a new mRNA platform that keeps vaccines and therapies effective in older adults and patients with obesity, where current treatments often lose potency.

(Nanowerk News) Researchers have engineered a redesigned regulatory region of messenger RNA that substantially boosts protein production and immune responses in preclinical models of aging and obesity, overcoming a major limitation of current mRNA therapeutics. The joint team, led by Professor Young-suk Lee from the KAIST Department of Bio and Brain Engineering and Professor Jae-Hwan Nam of The Catholic University of Korea, used large-scale bioinformatics analysis to identify optimized sequences for the 5′ untranslated region (5′UTR), a segment of mRNA that governs the initiation and rate of protein synthesis.

Key Findings

mRNA vaccines rose to global prominence during the COVID-19 pandemic, but their clinical utility extends well beyond infectious disease. The technology works by delivering genetic instructions into cells, prompting them to manufacture specific therapeutic proteins. A persistent challenge, however, is that efficacy tends to drop in elderly patients and those with obesity, two populations that often need these treatments most. The underlying issue relates to cellular stress. In aging and obese individuals, cells frequently operate under elevated oxidative stress, which impairs the molecular machinery responsible for translating mRNA into functional proteins. Rather than modifying the protein-coding portion of the mRNA molecule, the research team targeted the 5′UTR, a non-coding region that acts as a control switch for how quickly and abundantly proteins are synthesized. Schematic Diagram of mRNA Therapeutic Design and Validation Using Bioinformatics. (Image: KAIST) (click on image to enlarge) The mRNA molecule consists of several functional segments. The 5′UTR initiates and regulates the rate of protein production. The coding sequence (CDS) carries the genetic blueprint for a target protein. The 3′ untranslated region (3′UTR) helps stabilize the mRNA inside cells, and the poly(A) tail further supports stability and translation. While the 5′UTR and 3′UTR do not determine which protein is made, they critically influence how efficiently the protein is produced, making them attractive engineering targets. To pinpoint 5′UTR sequences capable of driving robust protein synthesis across diverse biological contexts, the team performed an integrated computational analysis drawing on multiple data modalities. These included RNA sequencing (RNA-seq) for profiling gene activity across tissues, single-cell RNA sequencing (scRNA-seq) for resolving gene expression at the individual cell level, and ribosome profiling (Ribo-seq) for directly measuring translation efficiency. The combined approach allowed the researchers to identify candidate sequences with broad efficacy rather than those optimized for a single tissue type. When the redesigned mRNA constructs were tested in preclinical models of aging and obesity, protein production and immune activation both improved markedly over existing mRNA designs. The results suggest that rational engineering of the 5′UTR can compensate for the stress-impaired translational capacity found in these conditions. Professor Young-suk Lee of KAIST stated, “This study identified a design strategy that enables mRNA to produce proteins more efficiently by analyzing large-scale biological data,” adding, “This technology will provide an important foundation for ensuring that mRNA vaccines and therapeutics remain effective even in environments where drug efficacy may decline, such as in elderly or obese patients.” The findings were published in Molecular Therapy (“Designing 5′ UTR sequences improves the capacity of mRNA therapeutics in preclinical models of aging and obesity”). The work represents a meaningful advance in mRNA therapeutic design by demonstrating that systematic, data-driven optimization of non-coding regulatory elements can restore drug performance in patient populations where conventional mRNA formulations fall short. As mRNA technology expands into cancer treatment, genetic disease therapy, and broader immunological applications, platforms capable of functioning reliably across physiologically diverse patients will be essential for realizing the full clinical potential of this technology class.